Important differences in intramyocellular lipids are likely to exist between insulin-sensitive athletes and insulin-resistant patients with type 2 diabetes, and if so, questions arise whether these differences could potentially be a target for manipulation in order to provide health improvements for patients. The gene discussed is INS; the disease is type 2 diabetes mellitus.